Bulletin
Investor Alert

New York Markets After Hours

press release

June 1, 2021, 9:20 a.m. EDT

Harrow Health Launches New Corporate and Investor Website

NASHVILLE, Jun 01, 2021 (GLOBE NEWSWIRE via COMTEX) -- NASHVILLE, Tenn., June 01, 2021 (GLOBE NEWSWIRE) -- Harrow Health, Inc. /zigman2/quotes/206805265/composite HROW +1.15% ("Harrow Health" or the "Company"), an ophthalmic-focused healthcare company, today announced the launch of its newly redesigned corporate and investor website, harrowinc.com . The new website, which is mobile-friendly, improves functionality and provides easy access to both historical and current information on the Company, including Letters to Stockholders and its Corporate Presentation . The website also provides detailed information about Harrow Health's journey to becoming one of the leading eye health companies in the United States, along with the Company's mission, vision and values, its product pipeline, and its quest to be a part of providing the gift of eyesight to Americans and people in areas around the world where eyecare isn't as readily available or affordable.

About Harrow Health
Harrow Health, Inc. /zigman2/quotes/206805265/composite HROW +1.15% is an ophthalmic-focused healthcare company. The Company owns ImprimisRx, the nation's leading ophthalmology outsourcing and pharmaceutical compounding business, and Visionology, a direct-to-consumer eye care subsidiary focused on chronic eye disease. Harrow Health also holds large equity positions in Eton Pharmaceuticals, Surface Ophthalmics and Melt Pharmaceuticals, all of which started as Harrow Health subsidiaries. Harrow Health also owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics and Melt Pharmaceuticals. For more information about Harrow Health, please visit the Investors section of the corporate website, harrowinc.com .

Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward-looking statements." Such forward-looking statements include, but are not limited to, statements regarding the intended use of proceeds. Because these forward-looking statements involve known and unknown risks and uncertainties, there are important factors that could cause actual results, events or developments to differ materially from those expressed or implied by these forward-looking statements. Additional risks and uncertainties are more fully described in Harrow Health's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2020. Such documents may be read free of charge on the SEC's web site at www.sec.gov . Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Except as required by law, Harrow Health undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

Contact:
Jamie Webb, Director of Communications and Investor Relations
jwebb@harrowinc.com
615-733-4737


COMTEX_387662652/2471/2021-06-01T09:19:48

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

(C) Copyright 2021 GlobeNewswire, Inc. All rights reserved.

/zigman2/quotes/206805265/composite
US : U.S.: Nasdaq
$ 9.66
+0.11 +1.15%
Volume: 87,199
Oct. 28, 2021 4:00p
P/E Ratio
37.01
Dividend Yield
N/A
Market Cap
$256.84 million
Rev. per Employee
$390,968
loading...
/zigman2/quotes/206805265/composite
US : U.S.: Nasdaq
$ 9.66
+0.11 +1.15%
Volume: 87,199
Oct. 28, 2021 4:00p
P/E Ratio
37.01
Dividend Yield
N/A
Market Cap
$256.84 million
Rev. per Employee
$390,968
loading...

Partner Center

Link to MarketWatch's Slice.